The Anti-Melanoma Efficiency of the Intratumoral Injection of Cucurbitacin-Loaded Sustained Release Carriers: In Situ-Forming Implants
- 258 Downloads
Our previous studies revealed that the PLGA-based particulate systems loaded with cucurbitacin showed limited anti-melanoma efficiency in xenograft animal models after intratumoral injection, which was due to the undesirable initial burst release and the leakage of the particulate carriers from the injection site through the pinhole. In this paper, two categories of in situ-forming implants (ISFIs) for intratumoral injection, PLGA ISFIs and SAIB ISFIs, were systemically evaluated for their potentials for on solid tumor treatment via intratumoral injection. The in vitro drug release profiles of these two ISFIs were different due to the different sol–gel transition properties. The pharmacodynamics results revealed that SAIB ISFIs displayed obvious therapeutic efficiencies to melanoma, and multi-points injection of SASIB ISFIs displayed better efficiency than single-point injection. The different sol–gel transition properties and mechanism for PLGA ISFIs and SAIB ISFIs affected both the drug release and strongly impacted the pharmacokinetic parameters and pharmacodynamic effectiveness. Also, the adhesive property of SAIB to the local tissue could extend the retention and inhibit the leakage of the SAIB ISFIs, thus enhanced the anticancer effectiveness. Comparison of the various intratumoral injection systems, appropriate drug release profiles (lower initial burst and steady release) and good retention (minimum leakage from the injection site) would benefit to the antitumor effects of the intratumoral depots.
KEY WORDSanti-melanoma efficiency cucurbitacin drug release in situ-forming implants (ISFIs) intratumoral injection
We thank Prof. Deng Yihui, Shenyang Pharmaceutical University, for his helpful comments on animal studies, Mr. Tian Han, Zhongshan School of Medicine, SUN YAT-SEN University, for his help on cellular experiments and results explanations, and Prof. Takshi Ikejima, Shenyang Pharmaceutical University, who kindly provided the A375.S2 human melanoma cell.
- 2.Dunn RL, Cowsar DR, Vanderbilt DP. Biodegradable in situ forming implants and methods of producing the same. 1990;U.S. Patent 4,938,763.Google Scholar
- 4.Dunn RL, Tipton AJ. Polymeric compositions useful as controlled release implant. 1997; U.S. Patent 5,702,716Google Scholar
- 9.Rhee YS, Park CW, DeLuca PP, Mansour HM. Sustained release injectable drug delivery systems. Pharm Tech. 2010;11(1):s6–s13.Google Scholar
- 12.Ravivarapu HB, Moyer KL, Dunn RL. Sustained activity and release of leuprolide acetate from a situ forming polymeric implant. AAPS Pharm Sci Technol. 2000;1(1):1–8.Google Scholar
- 17.Dong Xiaohui, The preparation of Cuc liposomes, The Master degree thesis of Shenyang Pharmaceutical University, 2008Google Scholar
- 24.Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients (6th edition), Pharmaceutical Press and the American Pharmacists Association, USA. 2009; pp. 17 (ethanol), 233 (DMSO), and 601 (NMP).Google Scholar